GPC3

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

Retrieved on: 
Tuesday, April 9, 2024
HCC, Malignancy, Disease, Lung, Patient, Bystander effect, Standard of care, Death, Spacecraft, IND, Investigational New Drug, Cancer, Drug resistance, Liver cancer, Therapy, ADC, Hepatocellular carcinoma, FDA, GPC3, Food, CDH3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027.

Key Points: 
  • SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027.
  • BC2027, which is BioCity's second first-in-class antibody drug conjugate (ADC) approved for clinical development, targets Glypican 3 (GPC3), a proteoglycan found in the outer membrane of cancer cells.
  • BC2027 binds with very high affinity to GPC3 and efficiently internalizes into cancer cells where it releases its cancer killing payload.
  • Dr. Yong Jiang Hei, CEO of BioCity, noted that "Drug resistance has increasingly become a challenge in cancer treatment.

Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy

Retrieved on: 
Monday, March 18, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, HCC, Canadian Aviation Regulations, Patient, GPC3, City, Cancer, Glypican 3, ARTEMIS, Clinical trial, Therapy, Safety, Liver cancer, Pharmaceutical industry

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
  • The ARYA-3 trial is evaluating Eureka’s investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advanced hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • The ARYA-3 trial has successfully completed Phase I and is now enrolling patients in Phase II.
  • Moving to Phase II marks a significant milestone in our mission to advance cutting-edge therapies for cancer treatment,” said Dr. Cheng Liu, President and CEO of Eureka Therapeutics.

AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Oncology, General Health, Health, Manufacturing, Clinical Trials, Partnership, Multimedia, Prostate cancer, Cell, Environment, Patient, University, TP53, Ecosystem, Quell, Glypican, IIT, AstraZeneca, Physician, Arm, Acquisition, STEAP2, GPC3, Cancer, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240206590080/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240206590080/en/
    New AstraZeneca facility in Rockville, Maryland (Photo: Business Wire)
    The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics , AbelZeta, Cellectis , and the acquisition of Neogene Therapeutics.
  • In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics, harnessing leading pharmaceutical technology and development.
  • AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune system’s T-cells to more effectively fight cancer.
  • Beyond this, the company is advancing a pipeline of novel T-cell receptor therapies (TCR-Ts) through Neogene Therapeutics, a wholly owned subsidiary of AstraZeneca.

Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

Retrieved on: 
Monday, January 22, 2024
HER2, Celltrion, VEGF, CD3, Stomach, Research, CSO, Ophthalmology, Partnership, Prospectus, GPC3, Form, ACAB, Hepatocellular carcinoma, Acquisition, Drug development, KRX, Therapy, Register, Breast, Engineering, Vaccine

Upon the closing of the proposed business combination, the combined company is expected to be named “Abpro Corporation” and to list its common stock on Nasdaq under the new ticker symbol “ABP”.

Key Points: 
  • Upon the closing of the proposed business combination, the combined company is expected to be named “Abpro Corporation” and to list its common stock on Nasdaq under the new ticker symbol “ABP”.
  • The proposed business combination sets Abpro’s implied pre-money equity valuation at $500 million.
  • Consistent with the recent signing of the Business Combination Agreement, the Atlantic Coastal and Abpro boards of directors have approved the proposed business combination, which is expected to be completed in the first half of 2024 subject to, among other things, the approval by Atlantic Coastal and Abpro stockholders, and other customary closing conditions.
  • Financial Group, LLC, is serving as financial advisor to Atlantic Coastal.

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

Retrieved on: 
Thursday, January 4, 2024
Research, Biotechnology, Other Health, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Molecular imaging, McKinsey & Company, IND, Drug development, Maastricht University, RWTH Aachen University, MBA, Alpha, MD, Doctor of Philosophy, Tsinghua University, Cancer, Investigational New Drug, Stanford University Medical Center, CA9, Patient, Radiopharmaceutical, Bristol Myers Squibb, Therapy, GPC3, Radiobiology

AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of Anna Karmann, MD, PhD as the company’s Chief Medical Officer based in San Francisco.

Key Points: 
  • AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of Anna Karmann, MD, PhD as the company’s Chief Medical Officer based in San Francisco.
  • Anna has over 15 years of experience in the biopharma industry, drug development, and clinical practice.
  • Anna holds an MD from RWTH Aachen University, a PhD from Maastricht University, and an MBA from RWTH Aachen University and Tsinghua University Beijing.
  • She gained significant clinical practice and clinical research experience at the University Medical Center Maastricht, Netherlands and Stanford University Hospital, CA, USA.

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

Retrieved on: 
Thursday, January 4, 2024
HER2, Biotechnology, Autoimmunity, FDA, Spacecraft, GEA, File, Publishing, Inflammation, Society, Cancer, Russell 3000 Index, Conference, IND, BTC, Prevalence, Jazz Pharmaceuticals, GPC3, Webcast, Patient, Senior, Environment, NASDAQ Biotechnology Index, BeiGene, Trial of the century, Standard of care, FIH, Publication, ADC, NBI, BLA, Pharmaceutical industry

Beyond ZW191, we are planning additional IND filings and FIH studies for ZW220 (NaPi2b) and ZW251 (GPC3) to commence in 2025.

Key Points: 
  • Beyond ZW191, we are planning additional IND filings and FIH studies for ZW220 (NaPi2b) and ZW251 (GPC3) to commence in 2025.
  • “Our strong financial position allows us to be opportunistic in evaluating additional R&D opportunities and pursuing potential strategic partnerships and collaborations.
  • We expect to submit INDs for ZW171 and ZW191 in 2024, and INDs for ZW220 and ZW251 in 2025.
  • An R&D Day to highlight our progress and future R&D strategy will be held in the fourth quarter of 2024.

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Retrieved on: 
Tuesday, December 26, 2023
Actinium, Hart–Scott–Rodino Antitrust Improvements Act, BMY, SSTR2, Bristol Myers Squibb, Hepatocellular carcinoma, Drug development, LLP, Acquisition, Centerview Partners, SAN, Carcinoma, BofA Securities, HCC, Covington & Burling, GMP, Cancer, CA9, Growth, Patient, Therapy, GPC3, Radioactive decay, Cooley LLP, Radiation, Pharmaceutical industry

PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
  • “Radiopharmaceutical therapeutics are already transforming cancer care, and RayzeBio is at the forefront of pioneering the application of this novel modality.
  • Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

ONK Therapeutics and NAYA Biosciences Announce Research Partnership to Advance Combination Therapy of Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies and FLEX-NK™ Bispecific Antibodies

Retrieved on: 
Wednesday, December 6, 2023
KO, AACR, Partnership, Survival, Tumor microenvironment, Antigen, Immunotherapy, Research, Kis, Natural killer T cell, Regenerative medicine, SAN, NCR1, Therapy, Fertility, Cancer, HCC, Society, CISH, Patient, GPC3, NK, FLEX, SITC

Specifically, the partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted NY-303 FLEX-NK™ bispecific antibody.

Key Points: 
  • Specifically, the partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted NY-303 FLEX-NK™ bispecific antibody.
  • The companies’ R&D teams will collaboratively evaluate ONK’s optimally gene-edited NK cell therapy, ONKT105, with NAYA’s NY-303 bispecific antibody before selecting the best candidates for potential clinical development.
  • ONK has exclusive, worldwide rights to KO of CISH in NK cells, regardless of the source of the NK cells.
  • They redirect and trigger the killing activity of Natural Killer (NK) cells towards their tumor targets using NKp46 activating receptors.

 Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Retrieved on: 
Tuesday, December 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Actinium, Hart–Scott–Rodino Antitrust Improvements Act, BMY, SSTR2, Bristol Myers Squibb, Hepatocellular carcinoma, Multimedia, Drug development, LLP, Acquisition, Centerview Partners, Carcinoma, BofA Securities, HCC, Covington & Burling, GMP, Cancer, CA9, Growth, Patient, Therapy, GPC3, Radioactive decay, Cooley LLP, Radiation, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
  • Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

Retrieved on: 
Monday, November 13, 2023
Sale, Research, Annual general meeting, SAN, Prevalence, Therapy, IND, Investment, Liver cancer, Biotechnology, Patient, Gene, GPC3, FDA, Immunotherapy, Neoplasm, Investigational New Drug, Celeste Nelson, SNTI, Cancer, SITC, CGMP, CMC, AML, Doctor of Philosophy, Synthetic biology, HCC, Society, Pharmaceutical industry, Vaccine, MD, Senti Aur Mental

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2023.

Key Points: 
  • “The third quarter was highly productive for Senti as we continued advancing SENTI-202 towards IND clearance and further developed our platform technology,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
  • Through this collaboration, Celest will lead clinical development, operations, and manufacturing for the advancement of SENTI-301A with technical support from Senti Bio.
  • Approximately 35% of Senti Bio’s employees transitioned from Senti Bio to GeneFab, which will support the clinical manufacturing of Senti Bio’s chimeric antigen receptor natural killer (CAR-NK) programs, including SENTI-202.
  • As of September 30, 2023, Senti Bio held cash, cash equivalents and short-term investments of $39.4 million.